Glycogen Storage Disease Type III diagnosis and management guidelines

Genetics in Medicine

Volumn 12, Issue 7, 2010, Pages 446-463

  Kishnani, Priya S ^a   Austin, Stephanie L ^a   Arn, Pamela ^b   Bali, Deeksha S ^a   Boney, Anne ^a   Case, Laura E ^a   Chung, Wendy K ^c   Desai, Dev M ^d   El Gharbawy, Areeg ^a   Haller, Ronald ^e   Smit, G Peter A ^a   Smith, Alastair D ^a   Hobson Webb, Lisa D ^a   Wechsler, Stephanie Burns ^a   Weinstein, David A ^f   Watson, Michael S ^g,h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NEMOURS CHILDREN S CLINIC   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d Departments of Surgery and Pediatrics   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h American College of Medical Genetics   (United States)

Author keywords

Cori disease; debranching enzyme deficiency; Forbes disease; glycogen storage disease type III; limit dextrinosis; management guidelines.

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLYCOGEN; GLYCOGEN DEBRANCHING ENZYME;

ALGORITHM; ATHEROSCLEROSIS; BLOOD CHEMISTRY; CARDIOMYOPATHY; CASE MANAGEMENT; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; CONTINUING EDUCATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ECG ABNORMALITY; ELECTROCARDIOGRAM; ENERGY METABOLISM; EXERCISE; GENE MUTATION; GENETIC COUNSELING; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE TYPE 1; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 4; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN STORAGE DISEASE TYPE 6; GLYCOGEN STORAGE DISEASE TYPE 7; HEART VENTRICLE HYPERTROPHY; HEPATOMEGALY; HUMAN; HYPOGLYCEMIA; INFANT NUTRITION; LIVER TRANSPLANTATION; MUTATIONAL ANALYSIS; MYOPATHY; PATHOPHYSIOLOGY; PEDIATRIC SURGERY; PHYSIOTHERAPY; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; REVIEW; GLYCOGEN STORAGE DISEASE TYPE III; LIVER; METABOLISM; PATHOLOGY; PROGNOSIS; SKELETAL MUSCLE;

GLYCOGEN STORAGE DISEASE TYPE III; HUMANS; LIVER; MUSCLE, SKELETAL; PROGNOSIS;

EID: 77955155274     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181e655b6     Document Type: Review

References (114)

1. Illingworth B, Cori GT. Structure of glycogens and amylopectins. III. Normal and abnormal human glycogen. J Biol Chem 1952;199:653-660.
2. Forbes GB. Glycogen storage disease: report of a case with abnormal glycogen structure in liver and skeletal muscle. J Pediatr 1953;42:645-653.
3. Illingworth B, Cori GT, Cori CF. Amylo-1,6-glucosidase in muscle tissue in generalized glycogen storage disease. J Biol Chem 1956;218:123-129.
4. Snappes I, Van Creveld S. Un cas d'hypoglycemie avec acetonemie chez un enfant. Bull Mem Soc Med Hop 1928;52:1315.
5. Van Creveld S, Huijing F. Differential diagnosis of the type of glycogen disease in two adult patients with long history of glycogenosis. Metabolism 1964;13:191-194.
6. Huijing F. Amylo-1,6-glucosidase activity in normal leucocytes and in leucocytes of patients with glycogen-storage disease. Clin Chim Acta 1964;9:269-272.
7. Yang BZ, Ding JH, Enghild JJ, Bao Y, Chen YT. Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranch-ing enzyme. J Biol Chem 1992;267:9294-9299.
8. Bao Y, Dawson TL Jr, Chen YT. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region. Genomics 1996;38:155-165.
9. Bao Y, Yang BZ, Dawson TL Jr, Chen YT. Isolation and nucleotide sequence of human liver glycogen debranching enzyme mRNA: identification of multiple tissue-specific isoforms. Gene 1997;197:389-398.
10. Howell R, Williams J. The glycogen storage diseases. In: Stanbury JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease, 5th ed. New York: McGraw-Hill; 1983:141.
11. Van Hoof F, Hers HG. The subgroups of type 3 glycogenosis. Eur J Bio-chem 1967;2:265-270.
12. Angelini C, Martinuzzi A, Vergani L. Glycogen storage diseases of muscle. In: Lane R, editor. Handbook of muscle diseases. New York, NY: Marcel Dekker; 1996:407.
13. Ding JH, de Barsy T, Brown BI, Coleman RA, Chen YT. Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III. J Pediatr 1990;116:95-100.
14. Sugie H, Fukuda T, Ito M, Sugie Y, Kojoh T, Nonaka I. Novel exon 11 skipping mutation in a patient with glycogen storage disease type IIId. J Inherit Metab Dis 2001;24:535-545.
15. Lee P, Burch M, Leonard JV. Plasma creatine kinase and cardiomyopathy in glycogen storage disease type III. J Inherit Metab Dis 1995;18:751-752.
16. Coleman RA, Winter HS, Wolf B, Chen YT. Glycogen debranching enzyme deficiency: long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis 1992;15:869-881.
17. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24:276-279.
18. Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, et al. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol 2007;46:492-498.
19. Siciliano M, De Candia E, Ballarin S, et al. Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease. J Clin Gastroenterol 2000;31:80-82.
20. Matern D, Starzl TE, Arnaout W, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999;158(suppl 2):S43-S48.
21. Cornelio F, Bresolin N, Singer PA, DiMauro S, Rowland LP. Clinical varieties of neuromuscular disease in debrancher deficiency. Arch Neurol 1984;41:1027-1032.
22. Hobson-Webb LD, Austin SL, Bali D, Kishnani PS. The electrodiagnostic characteristics of Glycogen Storage Disease Type III. Genet Med 2010;12:440-445.
23. Kotb MA, Abdallah HK, Kotb A. Liver glycogenoses: are they a possible cause of polyneuropathy? A cross-sectional study. J Trop Pediatr 2004; 50:196-202.
24. Labrune P, Huguet P, Odievre M. Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients. Pediatr Cardiol 1991;12:161-163.
25. Miller CG, Alleyne GA, Brooks SE. Gross cardiac involvement in glycogen storage disease type 3. Br Heart J 1972;34:862-864.
26. Moses SW, Wanderman KL, Myroz A, Frydman M. Cardiac involvement in glycogen storage disease type III. Eur J Pediatrics 1989;148:764-766.
27. Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV. Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 1997;79:834-838.
28. Shen J, Bao Y, Chen YT. A nonsense mutation due to a single base insertion in the 3'-coding region of glycogen debranching enzyme gene associated with a severe phenotype in a patient with glycogen storage disease type IIIa. Hum Mutat 1997;9:37-40.
29. Vertilus SM, Austin SL, Foster KS, et al. Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time. Genet Med 2010;12:413-423.
30. Cabrera-Abreu J, Crabtree NJ, Elias E, Fraser W, Cramb R, Alger S. Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX. J Inherit Metab Dis 2004;27:1-9.
31. Lee PJ, Patel A, Hindmarsh PC, Mowat AP, Leonard JV. The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulinism. Clin Endocrinol (Oxf) 1995;42:601-606.
32. Confino E, Pauzner D, Lidor A, Yedwab G, David M. Pregnancy associated with amylo-1,6-glucosidase deficiency (Forbe's disease). Case report. Br J Obstet Gynaecol 1984;91:494-497.
33. Bhatti S, Parry E. Successful pregnancy in a woman with glycogen storage disease type III. Aust N Z J Obstet Gynaecol 2006;46:168-169.
34. Mendoza A, Fisher NC, Duckett J, et al. Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol 1998;105:677-680.
35. Elpeleg ON. The molecular background of glycogen metabolism disorders. J Pediatr Endocrinol Metab 1999;12:363-379.
36. Lucchiari S, Fogh I, Prelle A, et al. Clinical and genetic variability of glycogen storage disease type IIIa: seven novel AGL gene mutations in the Mediterranean area. Am J Med Genet 2002;109:183-190.
37. Clayton PT. Diagnosis of inherited disorders of liver metabolism. J Inherit Metab Dis 2003;26:135-146.
38. Wolfsdorf JI, Holm IA, Weinstein DA. Glycogen storage diseases. Pheno-typic, genetic, and biochemical characteristics, and therapy. Endocrinol Metab Clin North Am 1999;28:801-823.
39. Lee P, Mather S, Owens C, Leonard J, Dicks-Mireaux C. Hepatic ultrasound findings in the glycogen storage diseases. Br J Radiol 1994;67:1062-1066.
40. Binkiewicz A, Senior B. Decreased ketogenesis in von Gierke's disease (type I glycogenosis). J Pediatr 1973;83:973-978.
41. Fernandes J, Pikaar NA. Ketosis in hepatic glycogenosis. Arch Dis Child 1972;47:41-46.
42. Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients. Causes and outcomes. N Engl J Med 1986;315:1245-1250.
43. Wolf AD, Lavine JE. Hepatomegaly in neonates and children. Pediatr Rev 2000;21:303-310.
44. Moses SW, Parvari R. The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med 2002;2:177-188.
45. Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med 2009;103:477-484.
46. Servidei S, Metlay LA, Chodosh J, DiMauro S. Fatal infantile cardiopathy caused by phosphorylase b kinase deficiency. J Pediatr 1988;113(1 Pt 1): 82-85.
47. Charpentier C, Saudubray J. Clinical phenotypes: diagnosis/algorithms. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A, editors. Scriver's online metabolic & molecular bases of inherited disease. New York, NY: McGraw-Hill; 2009.
48. Ugawa Y, Inoue K, Takemura T, Iwamasa T. Accumulation of glycogen in sural nerve axons in adult-onset type III glycogenosis. Ann Neurol 1986; 19:294-297.
49. Kiechl S, Kohlendorfer U, Thaler C, et al. Different clinical aspects of debrancher deficiency myopathy. J Neurol Neurosurg Psychiatry 1999;67:364-368.
50. Mineo I, Kono N, Hara N, et al. Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 1987;317:75-80.
51. Chen YT, Kishnani PS, Koeberl DD. Glycogen storage diseases. In: Valle D, Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A, editors. Scriver's online metabolic & molecular bases of inherited disease. New York, NY: McGraw-Hill; 2009.
52. McAdams AJ, Hug G, Bove KE. Glycogen storage disease, types I to X: criteria for morphologic diagnosis. Hum Pathol 1974;5:463-487.
53. DiMauro S, Hartwig GB, Hays A, et al. Debrancher deficiency: neuromus-cular disorder in 5 adults. Ann Neurol 1979;5:422-436.
54. Miranda AF, DiMauro S, Antler A, Stern LZ, Rowland LP. Glycogen debrancher deficiency is reproduced in muscle culture. Ann Neurol 1981; 9:283-288.
55. Shen JJ, Chen YT. Molecular characterization of glycogen storage disease type III. Curr Mol Med 2002;2:167-175.
56. Maire I, Baussan C, Moatti N, Mathieu M, Lemonnier A. Biochemical diagnosis of hepatic glycogen storage diseases: 20 years French experience. Clin Biochem 1991;24:169-178.
57. Shaiu WL, Kishnani PS, Shen J, Liu HM, Chen YT. Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease. Mol Genet Metab 2000;69:16-23.
58. DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York, NY: McGraw Hill; 1994: 1554-1579.
59. Maire I, Mathieu M. Possible prenatal diagnosis of type III glycogenosis. J Inherit Metab Dis 1986;9:89-91.
60. Shin YS. Diagnosis of glycogen storage disease. J Inherit Metab Dis 1990;13:419-434.
61. Besley GT, Cohen PT, Faed MJ, Wolstenholme J. Amylo-1,6-glucosidase activity in cultured cells: a deficiency in type III glycogenosis with prenatal studies. Prenat Diagn 1983;3:13-19.
62. Shin YS, Ungar R, Rieth M, Endres W. A simple assay for amylo-1,6-glucosidase to detect heterozygotes for glycogenosis type III in erythro-cytes. Clin Chem 1984;30:1717-1718.
63. Shin YS, Rieth M, Tausenfreund J, Endres W. First trimester diagnosis of glycogen storage disease type II and type III. J Inherit Metab Dis 1989; 12(suppl 2):289-291.
64. Yang BZ, Ding JH, Brown BI, Chen YT. Definitive prenatal diagnosis for type III glycogen storage disease. Am J Hum Genet 1990;47:735-739.
65. Goldstein JL, Austin SL, Boyette K, et al. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type III. Genet Med 2010;12:424-430.
66. Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996;98:352-357.
67. Okubo M, Horinishi A, Nakamura N, et al. A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb. Hum Genet 1998;102:1-5.
68. Cheng A, Zhang M, Okubo M, Omichi K, Saltiel AR. Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions. Hum Mol Genet 2009;18:2045-2052.
69. Lucchiari S, Santoro D, Pagliarani S, Comi GP. Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. Acta Myol 2007;26:72-74.
70. Pearson CM. Glycogen metabolism and storage diseases of types III, IV and V. Am J Clin Pathol 1968;50:29-43.
71. Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV. Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol 1984;53:980-981.
72. Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT. Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med 1992;116:896-900.
73. Carvalho JS, Matthews EE, Leonard JV, Deanfield J. Cardiomyopathy of glycogen storage disease type III. Heart Vessels 1993;8:155-159.
74. Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994;120:218-226.
75. Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K. Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J 1997;18:532-533.
76. Rossignol AM, Meyer M, Rossignol B, Palcoux MP, Raynaud EJ, Bost M. [Glycogenosis type III myocardiopathy]. Arch Fr Pediatr 1979;36:303-309.
77. Cochrane AB, Fedson SE, Cronin DC II. Nesiritide as bridge to multi-organ transplantation: a case report. Transplant Proc 2007;39:308-310.
78. Levine JC, Kishnani PS, Chen YT, Herlong JR, Li JS. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 2007;29:1033-1042.
79. Ogimoto A, Okubo M, Okayama H, et al. A Japanese patient with cardio-myopathy caused by a novel mutation R285X in the AGL gene. Circ J 2007;71:1653-1656.
80. Smit GP, Fernandes J, Leonard JV, et al. The long-term outcome of patients with glycogen storage diseases. J Inherit Metab Dis 1990;13:411-418.
81. Keddad KRS, Baussan C, Chalas J, et al. Blood lipids and rheological modifications in glycogen storage disease. Clin Biochem 1996;29:73-78.
82. Hershkovitz E, Donald A, Mullen M, Lee PJ, Leonard JV. Blood lipids and endothelial function in glycogen storage disease type III. J Inherit Metab Dis 1999;22:891-898.
83. Fernandes J, Leonard JV, Moses SW, et al. Glycogen storage disease: recommendations for treatment. Eur J Pediatr 1988;147:226-228.
84. Goldberg T, Slonim AE. Nutrition therapy for hepatic glycogen storage diseases. J Am Diet Assoc 1993;93:1423-1430.
85. Slonim AE, Coleman RA, Moses WS. Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy. J Pediatr 1984;105:906-911.
86. Slonim AE, Weisberg C, Benke P, Evans OB, Burr IM. Reversal of debrancher deficiency myopathy by the use of high-protein nutrition. Ann Neurol 1982;11:420-422.
87. Borowitz SM, Greene HL. Cornstarch therapy in a patient with type III glycogen storage disease. J Pediatr Gastroenterol Nutr 1987;6:631-634.
88. Mundy HR, Williams JE, Lee PJ, Fewtrell MS. Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit. J Inherit Metab Dis 2008;31:418-423.
89. Lee PJ, Ferguson C, Alexander FW. Symptomatic hyperinsulinism reversed by dietary manipulation in glycogenosis type III. J Inherit Metab Dis 1997;20:612-613.
90. Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet [published online ahead of print March 30, 2009]. J Inherit Metab Dis doi: 10.1007/s10545-009-1088-x.
91. Portmann B, Thompson RJ, Roberts EA, Paterson AC. Genetic and metabolic liver disease, 5 ed. London: Churchill Livingstone; 2007.
92. Cosme A, Montalvo I, Sanchez J, et al. [Type III glycogen storage disease associated with hepatocellular carcinoma]. Gastroenterol Hepatol 2005;28: 622-625.
93. Shimizu J, Shiraishi H, Sakurabayashi S, et al. [A report on an adult case of type III glycogenosis with primary liver cancer and liver cirrhosis]. Nippon Shokakibyo Gakkai Zasshi 1982;79:2328-2332.
94. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
95. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
96. Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 2008;12:137-145.
97. Iyer SG, Chen CL, Wang CC, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl 2007;13:848-852.
98. Moses SW, Gadoth N, Bashan N, Ben-David E, Slonim A, Wanderman KL. Neuromuscular involvement in glycogen storage disease type III. Acta Paediatr Scand 1986;75:289-296.
99. Tolun AA, Boyd KF, Austin SL, et al. Utility of a urinary tetrasaccharide as a biomarker for glycogen storage disease type III. In: 11th International Congress of Inborn Errors of Metabolism (ICIEM), San Diego, California; 2009.
100. Marbini A, Gemignani F, Saccardi F, Rimoldi M. Debrancher deficiency neuromuscular disorder with pseudohypertrophy in two brothers. J Neurol 1989;236:418-420.
101. Parvari R, Moses S, Shen J, Hershkovitz E, Lerner A, Chen YT. A single-base deletion in the 3-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients. Eur J Hum Genet 1997;5:266-270.
102. Kiechl S, Willeit J, Vogel W, Kohlendorfer U, Poewe W. Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. Neuromuscul Disord 1999;9:408-410.
103. Haller RG, Vissing J. Functional evaluation of metabolic myopathy. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York, NY: McGraw Hill; 2004:665-679.
104. Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 2006;59:922-928.
105. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996;15:135-157.
106. Oki Y, Okubo M, Tanaka S, Nakanishi K, Kobayashi T, Murase T. Diabetes mellitus secondary to glycogen storage disease type III. Diabet Med 2000;17:810-812.
107. Giannitrapani L, Soresi M, La Spada E, Cervello M, D'Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006;1089:228-236.
108. Mairovitz V, Labrune P, Fernandez H, Audibert F, Frydman R. Contraception and pregnancy in women affected by glycogen storage diseases. Eur J Pediatr 2002;161(suppl 1):S97-S101.
109. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, et al. A prospective study of the forearm bone density of users of etonorgestrel-and levonorg-estrel-releasing contraceptive implants. Hum Reprod 2006;21:466-470.
110. Lee P. Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol 1999; 106:181-182.
111. Ngai SH. Effects of anesthetics on various organs. N Engl J Med 1980; 302:564-566.
112. Mohart D, Russo P, Tobias JD. Perioperative management of a child with glycogen storage disease type III undergoing cardiopulmonary bypass and repair of an atrial septal defect. Paediatr Anaesth 2002;12:649-654.
113. Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 2006;29:332-340.
114. Gregory BL, Shelton GD, Bali DS, Chen YT, Fyfe JC. Glycogen storage disease type IIIa in curly-coated retrievers. J Vet Intern Med 2007;21: 40-46.